The Meyenburg Award, endowed with € 50,000, is one of the most prestigious distinctions in cancer research in Germany. Since its inception in 1981 under the auspices of the German Cancer Research Center (DKFZ), it has been awarded to scientists whose work has defined new paradigms in biology and medicine. Notably, several past recipients – including Andrew Fire, Elizabeth Blackburn, Shinya Yamanaka, Stefan Hell, Emmanuelle Charpentier, and, most recently, Katalin Karikó – went on to receive the Nobel Prize after being honored with the Meyenburg Award.
Awardee
Aviv Regev is the head of Genentech Research and Early Development. Prior to Genentech, Regev served as Chair of the Faculty, Core Member, and Founding director of the Klarman Cell observatory at the Broad Institute of MIT and Harvard, and as Professor of Biology at MIT and Investigator at the Howard Hughes Medical Institute.
She is a founding co-chair of the Human Cell Atlas. Regev has pioneered foundational experimental and computational methods in single-cell genomics, and is a leader in deciphering molecular circuits that govern cells, tissues and organs in health and and disease. Among many honors, she is an elected member of the US National Academy of Sciences and National Academy of Medicine.
